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16RESEARCH ARTICLE Open AccessImpact of diuretic therapy-associated electrolyte
disorders present on admission to the emergency
department: a cross-sectional analysis
Spyridon Arampatzis1,2, Georg-Christian Funk3, Alexander Benedikt Leichtle4, Georg-Martin Fiedler4,
Christoph Schwarz5, Heinz Zimmermann1, Aristomenis Konstantinos Exadaktylos1 and Gregor Lindner1*Abstract
Background: Diuretics are among the most commonly prescribed medications and, due to their mechanisms of
action, electrolyte disorders are common side effects of their use. In the present work we investigated the
associations between diuretics being taken and the prevalence of electrolyte disorders on admission as well as the
impact of electrolyte disorders on patient outcome.
Methods: In this cross sectional analysis, all patients presenting between 1 January 2010 and 31 December 2011 to
the emergency room (ER) of the Inselspital, University Hospital Bern, Switzerland were included. Data on diuretic
medication, baseline characteristics and laboratory data including electrolytes and renal function parameters were
obtained from all patients. A multivariable logistic regression model was performed to assess the impact of factors
on electrolyte disorders and patient outcome.
Results: A total of 8.5% of patients presenting to the ER used one diuretic, 2.5% two, and 0.4% three or four. In all,
4% had hyponatremia on admission and 12% hypernatremia. Hypokalemia was present in 11% and hyperkalemia in
4%. All forms of dysnatremia and dyskalemia were more common in patients taking diuretics. Loop diuretics were
an independent risk factor for hypernatremia and hypokalemia, while thiazide diuretics were associated with the
presence of hyponatremia and hypokalemia. In the Cox regression model, all forms of dysnatremia and dyskalemia
were independent risk factors for in hospital mortality.
Conclusions: Existing diuretic treatment on admission to the ER was associated with an increased prevalence of
electrolyte disorders. Diuretic therapy itself and disorders of serum sodium and potassium were risk factors for an
adverse outcome.
Keywords: Diuretics, Electrolyte disorders, OutcomeBackground
Diuretics are a mainstay of therapy for a wide variety of
diseases ranging from hypertension to the nephrotic
syndrome. Despite this key role, the various substances
used as diuretics can have serious side effects, such as
volume depletion, ototoxicity as with loop diuretics,
and, of course, the induction of electrolyte disorders [1].
In an ageing population, the number of patients treated* Correspondence: lindner.gregor@gmail.com
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distribution, and reproduction in any mediumwith diuretics for different indications is increasing, as
is the relevance of their side effects [2,3].
Studies investigating diuretic therapy-induced elec-
trolyte disorders have mainly focused on the effects of
thiazide diuretics. In a randomized controlled trial in
hypertensive patients, serum potassium levels were signifi-
cantly lower in patients treated with thiazide diuretics [4].
However, only patients who did not receive potassium
supplements developed marked hypokalemia with potas-
sium levels below 3.0 mmol/L [4]. A more recent study on
hypertensive patients found an incidence of 30% for
hyponatremia in patients treated with thiazide diuretics
[5]. The same study did not find an increased risk oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Baseline laboratory values
Substance Mean Standard deviation Number of patients (%)
Creatinine 82.0 64.0 17,813 (80)
Urea 6.4 5.1 15,513 (70)
Osmolality 304.0 23.0 3,524 (16)
Sodium 139.0 4.0 22,239 (100)
Potassium 3.5 0.6 22,165 (99)
Chloride 103.0 6.0 2,170 (10)
Phosphate 0.6 0.6 2,390 (11)
Calcium 2.0 0.2 8,267 (37)
Magnesium 0.8 0.1 5,339 (24)
All values are mmol/L, except creatinine (μmol/L) and osmolality (mosm/kg).
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hyponatremia [5].
To the best of our knowledge, the prevalence of diuretic
use and associated electrolyte disorders have never been
investigated in a large group of patients presenting to a
hospital emergency room (ER). Findings from large patient
series on the impact of non-thiazide diuretics on electro-
lyte levels are especially lacking.
Therefore, we investigated the associations between
diuretics being taken and the prevalence of electrolyte
disorders as well as the impact of electrolyte disorders
on patient outcome.
Methods
All patients admitted to the ER of the Inselspital, University
Hospital Bern, in whom serum sodium was measured
between 1 January 2009 and 31 December 2010 were
included in this cross-sectional analysis. During the
study period, 28,523 serum sodium measurements were
made in 22,239 patients.
For these 22,239 patients, we gathered data on age, sex,
admission type (medical or surgical), country of residence,
hospital admission, length of hospital stay, outcome and final
diagnosis as classified by the International Classification
of Diseases, 10th revision (ICD-10). We also screened the
patients’ medications for diuretic use. We gathered infor-
mation on diuretic use in accordance with the diuretic
substances licensed by the Swiss Agency for Therapeutic
Products (Swissmedic) as registered in the list of pharma-
ceutical products (http://www.kompendium.ch). Diuretic
agents combined with other substance classes such as anti-
hypertensive agents were also considered in the analysis.
We acquired information on the daily dose of the following
substances: hydrochlorothiazide, chlorthalidone, butizide,
amiloride, spironolactone, eplerenone, furosemide, tora-
semide, indapamide, metolazone and acetazolamide. Also,
if available, the levels of the following analytes were ob-
tained in the patients with serum sodium measurements:
potassium, chloride, calcium, phosphate, magnesium, cre-
atinine and urea. Using the values of these variables, the
patients were classed as having an electrolyte disorder or
not, based on the reference ranges of our central labora-
tory (sodium: 135 to 145 mmol/L, potassium: 3.5 to 4.7
mmol/L, chloride: 97 to 108 mmol/L, calcium: 2.1 to 2.55
mmol/L, phosphate: 0.84 to 1.45 mmol/L, magnesium:
0.75 to 1.00 mmol/L). We used baseline characteristics and
serum creatinine to calculate the estimated glomerular fil-
tration rate in accordance with the Modified Diet in Renal
Disease (MDRD) formula.
In the case of multiple admissions, only the first admis-
sion to the ER was considered for the analysis.
As this study was a retrospective analysis, there was no
need for informed consent. The study was approved by
the Ethics Committee of the Canton of Bern, Switzerland.Statistical analysis
Data are presented as means ± standard deviation (SD),
medians or proportions, as appropriate. Between-group
comparisons of continuous variables were performed
using the Mann–Whitney U test. Proportions were com-
pared using the χ2 test. When the expected count for
cells was lower than five, Fisher’s exact test or the exact
test module in SPSS was used.
Multivariable logistic regression analysis was used to ex-
plore the association of the various predictors with the
presence of electrolyte disorders and with hospitalization.
Predefined covariates were added to the logistic regression
models.
The cumulative hazard of death was calculated by the
Kaplan-Meier method and the log-rank test was used
for comparison of groups. Cox regression was used to
test associations of the electrolyte disorders with the
survival time adjusted for predefined covariates. A two-
sided P value of <0.05 was considered statistically signifi-
cant for all analyses. The statistical analysis was performed
using SPSS (SPSS for Windows V.17.0, Chicago, IL, USA).
Results
A total of 22,239 patients with serum sodium measure-
ments were included in the study. The mean age at pres-
entation was 52 years (SD 20 years) and 57% were men.
In all, 76% of patients were Swiss residents. Mean base-
line laboratory values are given in Table 1.
In all, 19,725 patients (88.7%) had no diuretic agent on
admission, while 1,884 (8.5%) had 1, 547 (2.5%) had 2,
and 83 (0.4%) had 3 or 4 different diuretic substances as
medication (Table 2). Loop diuretics were the most com-
mon, with 1,196 patients (48%) on torasemide and 231
(9%) on furosemide.
The mean serum sodium and serum chloride concentra-
tion were significantly lower in patients on diuretic medi-
cation on admission to the ER (138 ± 5 vs 139 ± 4 mmol/L,
and 101 ± 8 vs 103 ± 6 mmol/L, P <0.0001). The mean
serum potassium level was higher in patients on diuretics
Table 2 Overview of diuretic substances and dosage
Diuretic Number of patients (%) Median dose (mg) Quartile 1 Quartile 3
Torasemide 1.196 (48) 10 5 20
Furosemide 231 (9) 40 40 80
Hydrochlorothiazide 975 (39) 12.5 12.5 12.5
Chlorthalidone 102 (4) 12.5 12.5 25
Butizide 16 (1) 2.5 2.5 5
Amiloride 97 (4) 5 2.5 5
Spironolactone 403 (16) 25 25 50
Eplerenone 15 (1) 25 25 50
Indapamide 58 (2) 1.5 1.5 1.5
Metolazone 121 (5) 5 2.5 5
Acetazolamide 20 (1) 250 250 500
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diuretics on admission also had a significantly higher
mean serum creatinine concentration (116 ± 97 vs 78 ± 56
μmol/L, P <0.0001). Mean MDRD was higher in the group
without diuretic medication (58 ± 7 vs 51 ± 14).
In all, 845 patients (4% of patients with sodium mea-
surements) had hyponatremia on admission, 2,630 (12%)
hypernatremia, 246 (11%) hypochloremia, and 245 (11%)
had hyperchloremia. Hypokalemia was present in 2,459
(11%) and hyperkalemia was found in 974 (4%).
Hypophosphatemia was present in 611 (26%) patients,
hyperphosphatemia in 215 (9%), hypomagnesemia in 1,308
(24%), and hypermagnesemia in 244 (5%) patients.
Hypocalcemia was found in 956 (12%) and hypercalce-
mia in 108 (1%).
Hyponatremia was more common in patients taking
diuretic medication (20% vs 7.7%, P <0.0001). The abso-
lute number of different diuretics taken by patients was
associated with a higher prevalence of hyponatremia
(P <0.0001). A total of 14% of patients with hyponatremia
were taking loop diuretics, 12% thiazide-type diuretics, 6%
aldosterone antagonists, and 1% potassium-sparing di-
uretics. Hyponatremia was more likely to be seen in pa-
tients taking loop diuretics (OR 1.23), thiazide diuretics
(OR 1.48), potassium-sparing diuretics (OR 1.64) and
aldosterone antagonists (OR 2.45) than in patients without
diuretics (P <0.0001). In the multivariable regression
model, use of thiazide diuretics (odds ratio (OR) 1.44,
P <0.0001) and aldosterone antagonists (OR 2.4, P <0.0001)
were associated with the presence of hyponatremia after
correction for age, sex and estimated glomerular filtration
rate (eGFR) as calculated by MDRD.
Hypernatremia was more common in patients taking
diuretic medication (2.2% vs 1.6%, P = 0.03). As with
hyponatremia, the prevalence of hypernatremia rose with
the number of diuretic drugs taken (P = 0.02). Loopdiuretics were associated with a significantly higher
prevalence of hypernatremia than no diuretic treatment
(P = 0.0023). There was no significant difference for all
other types of diuretic agent (P >0.05). Use of loop di-
uretics was an independent risk factor for the presence of
hypernatremia after correction for age, sex and eGFR as
calculated by MDRD (OR 1.68, P = 0.0232).
Hypokalemia was significantly more common in pa-
tients under diuretic therapy (17% vs 11%, P <0.0001). In
patients taking loop diuretics (P = 0.0337), thiazide di-
uretics (P <0.0001) and potassium-sparing diuretics
(P <0.0001), hypokalemia was more common than in pa-
tients on no diuretic therapy. No difference was seen for
aldosterone antagonists (P = 0.7) or carboanhydrase inhib-
itors (P = 0.9). In the multivariable regression model, loop
diuretics (OR 1.27, P = 0.0316), thiazide diuretics (OR 2.18,
P <0.0001) and potassium-sparing diuretics (OR 2.13,
P = 0.0038) were associated with the presence of hypokal-
emia. Male sex (OR 0.61, P <0.0001) was also associated
with a lower risk for hypokalemia.
Hyperkalemia was significantly more common in pa-
tients on diuretic therapy (13% vs 4%, P <0.0001). The
prevalence of hyperkalemia was linked to the number of
diuretic agents taken by patients (P <0.0001). All types of
diuretics were associated with an increased prevalence of
hyperkalemia (P <0.05). In the multivariable regression
model, potassium-sparing diuretics (OR 3.3, P = 0.0044),
aldosterone antagonists (OR 1.76, P <0.0015) and age (OR
1.03, P <0.0001), male sex (OR 1.35, P <0.0001) and serum
creatinine (OR 2.23, P <0.0001) were associated with the
presence of hyperkalemia (a higher MDRD was protective
for the presence of hyperkalemia, OR 0.93, P <0.0001).
Thiazide diuretics were associated with a lower risk of
hyperkalemia (OR 0.65, P = 0.0054).
In the multivariable regression model, the presence of
hyponatremia (OR 1.29, P = 0.0117) and advanced age
Figure 2 Kaplan-Meier curve for mortality in patients with
hypokalemia (OR 1.89, P <0.0001) or hyperkalemia (OR 2.35,
P <0.0001) versus patients with normal serum sodium.
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hospitalization, while male sex was associated with a lower
risk for a need for hospitalization (OR 0.86, P = 0.0186).
Overall, in-hospital mortality was 2.6%. The in-hospital
mortality of patients with hyponatremia was 6.8% and
was 2.6% for patients with hypernatremia. Patients with
hypokalemia had an in-hospital mortality of 4.5%, while
10.4% of patients with hyperkalemia died. Both hypo-
natremia (OR 1.55, P = 0.0003) and hypernatremia (OR
3.21, P <0.0001) were predictors for increased mortality in
the multivariable regression model after correction for
age, sex and eGFR as calculated by MDRD. The presence
of hypokalemia (OR 1.89, P <0.0001) or hyperkalemia (OR
2.35, P <0.0001) on admission was also associated with
higher mortality in hospital. Figures 1 and 2 show Kaplan-
Meier curves for mortality in patients with dysnatremias
and dyskalemias and for those with normal serum sodium
concentrations.
Diuretic use and the number of diuretics on admission
as well as serum creatinine and age were also associated
with increased in-hospital mortality (P <0.0001).
Discussion
Over a 2-year period, more than 20,000 patients seen in
our ER at a large tertiary care hospital for different rea-
sons had serum sodium measurements, which was the
prime variable for inclusion in our study. A total of 11%
of these patients were taking diuretic agents, and 3%
were taking more than one diuretic agent.
Serum sodium levels were significantly lower in patients
under diuretic treatment and significantly more patients
with hyponatremia were taking a diuretic on admission.
Interestingly, potassium levels were significantly higher in
patients under diuretic therapy than in those without
diuretics. Hypokalemia, however, was significantly more
often seen in patients on diuretic agents. Loop diureticsFigure 1 Kaplan-Meier curve for mortality in patients with
hyponatremia (OR 1.55, P = 0.004) or hypernatremia (OR 3.21,
P = 0.0001) versus patients with normal serum sodium.were an independent risk factor for hypernatremia and
hypokalemia and thiazide use was associated with the
presence of hyponatremia and hypokalemia while they
were protective against hyperkalemia. The use of aldos-
terone antagonists was an independent risk factor for
the presence of hyponatremia and hyperkalemia. In a
Cox regression model, all forms of dysnatremia and
dyskalemia were independent risk factors for in-hospital
mortality.
To the best of our knowledge, this is the first study in-
vestigating the associations between all types of diuretic
and electrolyte levels in a large group of patients present-
ing to the ER of a major teaching hospital. Our finding of
an association between thiazide diuretic and hyponatremia
and hypokalemia confirms the results of previous studies
[2,4-7]. The association between hypernatremia and loop
diuretic use is explained by the mechanism of action of
loop diuretics where the excretion of electrolyte-free water
exceeds the increased natriuresis [8]. The mechanism of
action of aldosterone antagonists explains their associ-
ation with hyponatremia and hyperkalemia in the present
study [8].
We found that hyponatremia and hypernatremia on
admission are associated with increased mortality and
this supports results from previous studies by our group
[9-11]. A recent study in patients with myocardial infarc-
tion also found increased mortality in patients with
hypokalemia and hyperkalemia, supporting our findings
on the untoward effects of dyskalemias on outcome [12].
Although our study cannot demonstrate causality, the
effects of electrolyte disorders on different physiological
functions suggest an independent effect on mortality
[13-17]. This puts the relevance of diuretic therapy-
induced electrolyte disorders into a new light: should pa-
tients at risk of developing an electrolyte disorder from a
certain diuretic be treated with a different substance? This
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thiazide-induced hyponatremia [18,19]. A further option
would be to more strongly encourage electrolyte supple-
mentation since this appears to be beneficial [4]. What at
least seems crucial is to create awareness in physicians
prescribing diuretic therapy that regular electrolyte moni-
toring should be performed to identify those who may de-
velop the adverse effects of electrolyte disorders, such as
an increased risk of falls or fractures [14,20].
Vasopressin antagonists are the currently newest type
of diuretic medication on the market. Today, indica-
tions for vasopressin antagonists include euvolemic and
hypervolemic hyponatremia [21]. With these new diuretic
agents new side effects can be expected: Due to their
mechanism of action, namely an inhibition of vasopressin
action, overshooting “corrections” of serum sodium could
occur. Additionally, hypovolemia and its effects such as
dizziness were described in studies on vasopressin antago-
nists [22].
One of the limitations of our study is that it was not
practicable to obtain data on and evaluate all medications
the patients were taking because of the large number of
patients included. Information on other substances that
may influence serum electrolytes, such as angiotensin-
converting enzyme inhibitors, was not available. We also
only had information on the patient’s principal diagnosis,
thus excluding secondary diagnoses as potential contribu-
tory factors, such as cirrhosis of the liver. One of the
strengths of the study, however, was the large number of
patients included, and we therefore do not expect that
these limitations had a substantial effect on our findings.
Conclusions
The spectrum of electrolyte disorders in patients on di-
uretics admitted to our ER varied with the class of diuretic.
All diuretics were associated with an increased prevalence
of electrolyte disorders on admission. Diuretic therapy it-
self and disorders of serum sodium and potassium were
risk factors for an adverse outcome.
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